Tests engineered immune cells against solid tumors in adults with cancer
Tests modified immune cells in adults with solid cancers that express GPC3 or mesothelin.
Plain-language title generated from the registry record
Registry title: GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06196294, who can take part
Where in China
- The second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital of Guangzhou Medical University
- Trial code
- NCT06196294
- Record updated
- 26 June 2024
- Original description
The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.Read full original descriptionShow less
GPC3/Mesothelin Targeted CAR-γδT for Immunotherapy of Solid Cancer: Phase I Clinical Trial
The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.
Inclusion: Patients with advanced cancer that expresses GPC3 or Mesothelin protein; 2. Life expectancy >12 weeks; 3. Adequate heart, lung, liver, kidney, and blood function; 4. Available autologous transduced T cells with greater than or equal to 20% expression of GPC3/Mesothelin-CAR determined by flow-cytometry and killing of Mesothelin-positive targets greater than or equal to 20% in cytotoxicity assay; 5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent; -.
Exclusion: Had accepted gene therapy before; Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day); Severe virus infection such as HBV, HCV, HIV, et al; Known HIV positivity; Active infectious disease related to bacteria, virus,fungi,et al; Other severe diseases that the investigators consider not appropriate; Other conditions that the investigators consider not appropriate. -; Pregnant or lactating women.